Azurity Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AZURITY, and when can generic versions of AZURITY drugs launch?
AZURITY has thirty-two approved drugs.
There are eighty-six US patents protecting AZURITY drugs.
There are three hundred and forty patent family members on AZURITY drugs in forty-eight countries and forty-one supplementary protection certificates in fifteen countries.
Summary for Azurity
International Patents: | 340 |
US Patents: | 86 |
Tradenames: | 31 |
Ingredients: | 24 |
NDAs: | 32 |
Patent Litigation for Azurity: | See patent lawsuits for Azurity |
Drugs and US Patents for Azurity
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Azurity | SOTYLIZE | sotalol hydrochloride | SOLUTION;ORAL | 205108-001 | Oct 22, 2014 | RX | Yes | Yes | 11,850,222 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Azurity | ERYPED | erythromycin ethylsuccinate | GRANULE;ORAL | 050207-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Azurity | KONVOMEP | omeprazole; sodium bicarbonate | FOR SUSPENSION;ORAL | 213593-001 | Aug 30, 2022 | RX | Yes | Yes | 11,633,478 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Azurity | ERY-TAB | erythromycin | TABLET, DELAYED RELEASE;ORAL | 062298-003 | Mar 29, 1982 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Azurity | KATERZIA | amlodipine benzoate | SUSPENSION;ORAL | 211340-001 | Jul 8, 2019 | RX | Yes | Yes | 10,959,991 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Azurity | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-001 | Apr 6, 2011 | RX | Yes | Yes | 8,026,279 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Azurity
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Azurity | GLIADEL | carmustine | IMPLANT;INTRACRANIAL | 020637-001 | Sep 23, 1996 | 5,179,189 | ⤷ Try a Trial |
Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-001 | Jan 30, 2019 | 10,130,580 | ⤷ Try a Trial |
Azurity | HORIZANT | gabapentin enacarbil | TABLET, EXTENDED RELEASE;ORAL | 022399-001 | Apr 6, 2011 | 8,048,917 | ⤷ Try a Trial |
Azurity | GLIADEL | carmustine | IMPLANT;INTRACRANIAL | 020637-001 | Sep 23, 1996 | 4,757,128 | ⤷ Try a Trial |
Azurity | EVEKEO ODT | amphetamine sulfate | TABLET, ORALLY DISINTEGRATING;ORAL | 209905-005 | Apr 16, 2021 | 10,130,580 | ⤷ Try a Trial |
Azurity | BIDIL | hydralazine hydrochloride; isosorbide dinitrate | TABLET;ORAL | 020727-001 | Jun 23, 2005 | 4,868,179 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for AZURITY drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Oral Solution | 1 mg/mL | ➤ Subscribe | 2018-08-31 |
➤ Subscribe | Powder for Oral Solution | 1 mg/mL | ➤ Subscribe | 2016-06-21 |
International Patents for Azurity Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Norway | 333756 | ⤷ Try a Trial |
Portugal | 2124903 | ⤷ Try a Trial |
Slovenia | 2500014 | ⤷ Try a Trial |
Russian Federation | 2006133898 | ⤷ Try a Trial |
European Patent Office | 3145527 | ⤷ Try a Trial |
Israel | 159300 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Azurity Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2317997 | 2190050-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212 |
1718641 | CA 2012 00013 | Denmark | ⤷ Try a Trial | |
0443983 | C300445 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016 |
0260415 | SPC/GB01/013 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: N,N'-BIS(2-CHLOROETHYL)-N-NITROSO-UREA (CARMUSTINE) COMBINED WITH A POLYANHYDRIDE HAVING A WEIGHT AVERAGE MOLECULAR WEIGHT OF GREATER THAN 20,000 PREPARED BY THE POLYCONDENSATION OF: (I) 4,4'-(TRIMETHYLENEDIOXY)-DIBENZOIC ACID; AND (II) SEBACIC ACID (POLI; REGISTERED: FR 561 907-5 19990105; UK PL 00012/0337 20000928 |
1507558 | 12C0033 | France | ⤷ Try a Trial | PRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: CH - 6167801 20110705 |
0678503 | C300499 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.